Risk Factors for Polypharmacy in Older Adults

Status Completed

Clinical Trial Summary

Patients who were 65 years old or older and applied to Melek Hatun family practice center were enrolled in the study. All patients were seen either in our center or in their homes, and informed consents were obtained. Comprehensive Geriatric Assessment (CGA) was performed for each subject. Data were evaluated by PASW 17. The amount of medicines that the patient used everyday (DDC) was dependent variable. Relationships between DDC and other continuous variables were examined by Pearson's correlation. For categorical independent variables, t-tests were performed.

Clinical Trial Description

1000 patients who were 65 years old or older and applied to Melek Hatun family practice center either in person or through a relative between 01 December 2014 and 01 August 2017 were enrolled in the study. All patients were seen either in our center or in their homes, and informed consents were obtained. Comprehensive Geriatric Assessment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up & Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL & IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG &TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject[8-16]. Additional tests like blood examinations or ECG were performed on the basis of necessity. Metabolic Syndrome (MS) was diagnosed according to WHO criteria [17].

Data were evaluated by PASW 17. The amount of medicines that the patient used everyday (Daily Drug Consumption-DDC) were dependent variable. Relationships between DDC and other continuous variables were examined by Pearson's correlation. For categorical independent variables, t-tests were performed. The variables which were found associated with DDC were controlled for confounding variables by linear regressions. To avoid collinearity problems, variables that were strongly interrelated (like CD and MMSE) were not added to the regression model together. For all analyses, the level of significance was assumed as 0.05. ;

Study Design

Related Conditions & MeSH terms

Polypharmacy

Clinical Trial Details

NCT number	NCT03524560
Study type	Observational [Patient Registry]
Source	Karabuk University
Contact
Status	Completed
Phase
Start date	December 1, 2014
Completion date	December 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03688542` - Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module	N/A
Completed	`NCT02545257` - Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care	N/A
Withdrawn	`NCT01932632` - Medication Minimization for Long-term Care Residents	N/A
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Active, not recruiting	`NCT04181879` - Appropriate Polypharmacy in Older People in Primary Care	N/A
Not yet recruiting	`NCT03283735` - Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal	N/A
Completed	`NCT02918058` - Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults	N/A
Completed	`NCT03655405` - Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents	N/A
Completed	`NCT04575155` - Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management	N/A
Withdrawn	`NCT05816967` - Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients	N/A
Completed	`NCT05616689` - Bundled Hyperpolypharmacy Deprescribing	N/A
Terminated	`NCT04055896` - Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting	N/A
Active, not recruiting	`NCT03052192` - Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
Completed	`NCT02866799` - Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy	N/A
Completed	`NCT01732302` - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients	N/A
Enrolling by invitation	`NCT05053815` - Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Active, not recruiting	`NCT04585191` - Reducing Treatment Risk in Older Adults With Diabetes	N/A
Active, not recruiting	`NCT04120480` - Effectiveness of PGx Testing	N/A
Recruiting	`NCT05609981` - Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems	N/A
Recruiting	`NCT05501223` - Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.